Friday, February 12, 2016

Tuesday Features

DiaMedica readies bridging study of DM199 protein

DiaMedica readies bridging study of DM199 protein

Rick Pauls DiaMedica (OTCQB:DMCAF; TSX-V:DMA) is preparing to begin a bridging study in the first half this year to determine the relative potency, and best dose and delivery of its lead recombinant protein, DM199. “Our near-term focus is advancing DM199 into clinical studies for the treatment of acute ischemic stroke and positioning DM199 to provide... [Read more of this feature]


In conversation with Amir Ronen

In conversation with Amir Ronen

Amir Ronen As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior management roles at leading global companies, including VP of marketing and business development at M-Systems, which was acquired by... [Read more of this feature]


In conversation with Dr. Alan Schwebel

In conversation with Dr. Alan Schwebel

Dr. Alan Schwebel As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel, who has more than 30 years of experience in senior management positions in leading medical device and medical diagnostic companies,... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Avivagen begins trial of OxC-beta with UNAHCO

Avivagen begins trial of OxC-beta with UNAHCO

Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry. Trial design reflects a collaboration between Avivagen and UNAHCO and it will measure the benefits of OxC-beta on the performance and welfare of broiler poultry raised... [Read more of this brief]


Fresenius extends Endexo accord with Interface Biologics

Fresenius extends Endexo accord with Interface Biologics

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis market, including continuous renal replacement therapy. Interface’s Endexo is a self-locating fluoro-oligomeric additive that results... [Read more of this brief]


Titan Medical prices overnight offering

Titan Medical prices overnight offering

Titan Medical (OTCQX:TITXF; TSX:TMD) has priced an overnight marketed offering of equity securities, issuing up to 8,888,889 units at a price of 90 cents each for gross proceeds of about $8-million. Each unit consists of one common share of the company and one warrant. Each warrant is exercisable at a price of $1 to acquire one additional common share... [Read more of this brief]


Microbix developing program to combat Zika virus

Microbix developing program to combat Zika virus

Microbix Biosystems (TSX:MBX) has made plans to develop and introduce new products for use in diagnostic tests and vaccine research in response to the emergent Zika virus, which is spreading throughout the Americas and is being characterized as a crisis by health authorities. The Zika virus is a member of the flavivirus family, which includes the mosquito-borne... [Read more of this brief]


Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+